clinicaltrialsarena

EASD 2026: Lilly’s amylin-tirzepatide combo beats its weight loss drug alone

Lilly has already made a name for itself in the weight loss arena. Credit: JHVEPhoto / Shutterstock.com Eli Lilly’s EloraTZP, a combination of eloralintide and tirzepatide, has proven more efficacious ...
clinicaltrialsarena

VectorY broadens global PIONEER-ALS clinical trial cohort

ALS is a fatal neurodegenerative condition with no cure and limited treatment options for symptom management. Credit: Andrzej Rostek/Shutterstock.com. VectorY Therapeutics has expanded the study size ...
clinicaltrialsarena

Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss

Rafael Holdings subsidiary, Cyclo Therapeutics is planning to submit a NDA to US regulators for Trappsol Cyclo in NPC despite the primary endpoint miss. Credit: Kateryna Kon / Shutterstock.com. Rafael ...
clinicaltrialsarena

EASD 2026: Oral semaglutide drives weight loss after switch from injectable GLP-1s

Oral semaglutide maintains weight-loss progress after injectable GLP-1 therapy, strengthening its case as an oral alternative.
clinicaltrialsarena

MSD’s Phase IIb study of tulisokibart achieves primary endpoint

In the study, 72% of patients in the high-dose arm and 64% in the medium-dose arm achieved HiSCR50. Credit: 89stocker / Shutterstock.com. Merck & Co (MSD) has reported that the Phase IIb MK-7240-012 ...
clinicaltrialsarena

IMS26: Key readouts rock the multiple myeloma field amid shifting landscape

The Clinical Trials Arena editorial team brings you the highlights from the IMS 2026 Congress in Glasgow, Scotland. Credit: David A Litman / Shutterstock.com. In recent years, the multiple myeloma ...
clinicaltrialsarena

Akeso begins Phase III study of cadonilimab for gastric cancer

The bispecific antibody is intended for treating advanced gastric cancer. Credit: SewCreamStudio/Shutterstock.com. Akeso has commenced a global Phase III clinical ...
clinicaltrialsarena

Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss

Acadia is continuing its Phase III studies on remlifanserin in ADP with some protocol amendments. Credit: Chinnapong / Shutterstock.com. Acadia Pharmaceuticals has deemed the results of its Phase II ...
clinicaltrialsarena

Alkermes reports positive top-line Phase Ib trial data for ALKS 7290

Adults with ADHD treated with ALKS 7290 experienced dose-dependent, clinically meaningful improvements in symptom severity at day 14. Credit: Faizal Ramli / Shutterstock.com. Alkermes has reported ...
clinicaltrialsarena

Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial

Vasomune Therapeutics will focus on data quality, review, cleaning, site closeout, and database lock preparations. Credit: PanuShot / Shutterstock.com. Vasomune Therapeutics has completed enrolment in ...
clinicaltrialsarena

Kyverna’s stiff-person syndrome trial shows one-year durability

SPS is a rare, progressive autoimmune neurological disorder that causes severe muscle stiffness, rigidity, and painful spasms. Credit: Jack_the_sparow / Shutterstock.com Kyverna Therapeutics’ Phase ...